Andrew M. Fang, Brian F. Chapin, Charles W. Shi, Jia Sun, Aliya Qayyum, Vikas Kundra, Paul G. Corn, Deborah A. Kuban, Gregory C. Ravizzini, Devaki Shilpa S. Surasi, Jingfei Ma, Tharakeswara K. Bathala
{"title":"全身磁共振成像为高危前列腺癌患者分期","authors":"Andrew M. Fang, Brian F. Chapin, Charles W. Shi, Jia Sun, Aliya Qayyum, Vikas Kundra, Paul G. Corn, Deborah A. Kuban, Gregory C. Ravizzini, Devaki Shilpa S. Surasi, Jingfei Ma, Tharakeswara K. Bathala","doi":"10.1038/s41391-024-00893-1","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Staging patients with high-risk prostate cancer (HRPCa) with conventional imaging of computed tomography (CT) and bone scintigraphy (BS) is suboptimal. Therefore, we aimed to compare the accuracy of whole-body magnetic resonance imaging (WBMRI) with conventional imaging to stage patients with HRPCa.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We prospectively enrolled patients with newly diagnosed HRPCa (prostate‐specific antigen ≥20 ng/ml and/or Grade Group ≥4). Patients underwent BS, CT of the abdomen and pelvis, and WBMRI within 30 days of evaluation. The primary endpoint was the diagnostic performances of detecting metastatic disease to the lymph nodes and bone for WBMRI and conventional imaging. The reference standard was defined by histopathology or by all available clinical information at 6 months of follow-up. To compare diagnostic tests, Exact McNemar’s test and area under the curve (AUC) of the receiver operating characteristics curves were utilized.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Among 92 patients enrolled, 15 (16.3%) and 8 (8.7%) patients were found to have lymphatic and bone metastases, respectively. The sensitivity, specificity, and accuracy of WBMRI in detecting lymphatic metastases were 0.60 (95% confidence interval 0.32–0.84), 0.84 (0.74–0.92), and 0.80 (0.71–0.88), respectively, while CT were 0.20 (0.04–0.48), 0.92 (0.84–0.97), and 0.80 (0.71–0.88). The sensitivity, specificity, and accuracy of WBMRI to detect bone metastases were 0.25 (0.03–0.65), 0.94 (0.87–0.98), and 0.88 (0.80–0.94), respectively, while CT and BS were 0.12 (0–0.53), 0.94 (0.87–0.98), and 0.87 (0.78–0.93). For evaluating lymphatic metastases, WBMRI demonstrated a higher sensitivity (<i>p</i> = 0.031) and discrimination compared to CT (0.72 versus 0.56, <i>p</i> = 0.019).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>For staging patients with HRPCa, WBMRI outperforms CT in the detection of lymphatic metastases and performs as well as CT and BS in the detection of bone metastases. Further studies are needed to assess the cost effectiveness of WBMRI and the utility of combined PSMA PET and WBMRI.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"196 1","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer\",\"authors\":\"Andrew M. Fang, Brian F. Chapin, Charles W. Shi, Jia Sun, Aliya Qayyum, Vikas Kundra, Paul G. Corn, Deborah A. Kuban, Gregory C. Ravizzini, Devaki Shilpa S. Surasi, Jingfei Ma, Tharakeswara K. Bathala\",\"doi\":\"10.1038/s41391-024-00893-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Background</h3><p>Staging patients with high-risk prostate cancer (HRPCa) with conventional imaging of computed tomography (CT) and bone scintigraphy (BS) is suboptimal. Therefore, we aimed to compare the accuracy of whole-body magnetic resonance imaging (WBMRI) with conventional imaging to stage patients with HRPCa.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>We prospectively enrolled patients with newly diagnosed HRPCa (prostate‐specific antigen ≥20 ng/ml and/or Grade Group ≥4). Patients underwent BS, CT of the abdomen and pelvis, and WBMRI within 30 days of evaluation. The primary endpoint was the diagnostic performances of detecting metastatic disease to the lymph nodes and bone for WBMRI and conventional imaging. The reference standard was defined by histopathology or by all available clinical information at 6 months of follow-up. To compare diagnostic tests, Exact McNemar’s test and area under the curve (AUC) of the receiver operating characteristics curves were utilized.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>Among 92 patients enrolled, 15 (16.3%) and 8 (8.7%) patients were found to have lymphatic and bone metastases, respectively. The sensitivity, specificity, and accuracy of WBMRI in detecting lymphatic metastases were 0.60 (95% confidence interval 0.32–0.84), 0.84 (0.74–0.92), and 0.80 (0.71–0.88), respectively, while CT were 0.20 (0.04–0.48), 0.92 (0.84–0.97), and 0.80 (0.71–0.88). The sensitivity, specificity, and accuracy of WBMRI to detect bone metastases were 0.25 (0.03–0.65), 0.94 (0.87–0.98), and 0.88 (0.80–0.94), respectively, while CT and BS were 0.12 (0–0.53), 0.94 (0.87–0.98), and 0.87 (0.78–0.93). For evaluating lymphatic metastases, WBMRI demonstrated a higher sensitivity (<i>p</i> = 0.031) and discrimination compared to CT (0.72 versus 0.56, <i>p</i> = 0.019).</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p>For staging patients with HRPCa, WBMRI outperforms CT in the detection of lymphatic metastases and performs as well as CT and BS in the detection of bone metastases. Further studies are needed to assess the cost effectiveness of WBMRI and the utility of combined PSMA PET and WBMRI.</p>\",\"PeriodicalId\":20727,\"journal\":{\"name\":\"Prostate Cancer and Prostatic Diseases\",\"volume\":\"196 1\",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostate Cancer and Prostatic Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41391-024-00893-1\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41391-024-00893-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer
Background
Staging patients with high-risk prostate cancer (HRPCa) with conventional imaging of computed tomography (CT) and bone scintigraphy (BS) is suboptimal. Therefore, we aimed to compare the accuracy of whole-body magnetic resonance imaging (WBMRI) with conventional imaging to stage patients with HRPCa.
Methods
We prospectively enrolled patients with newly diagnosed HRPCa (prostate‐specific antigen ≥20 ng/ml and/or Grade Group ≥4). Patients underwent BS, CT of the abdomen and pelvis, and WBMRI within 30 days of evaluation. The primary endpoint was the diagnostic performances of detecting metastatic disease to the lymph nodes and bone for WBMRI and conventional imaging. The reference standard was defined by histopathology or by all available clinical information at 6 months of follow-up. To compare diagnostic tests, Exact McNemar’s test and area under the curve (AUC) of the receiver operating characteristics curves were utilized.
Results
Among 92 patients enrolled, 15 (16.3%) and 8 (8.7%) patients were found to have lymphatic and bone metastases, respectively. The sensitivity, specificity, and accuracy of WBMRI in detecting lymphatic metastases were 0.60 (95% confidence interval 0.32–0.84), 0.84 (0.74–0.92), and 0.80 (0.71–0.88), respectively, while CT were 0.20 (0.04–0.48), 0.92 (0.84–0.97), and 0.80 (0.71–0.88). The sensitivity, specificity, and accuracy of WBMRI to detect bone metastases were 0.25 (0.03–0.65), 0.94 (0.87–0.98), and 0.88 (0.80–0.94), respectively, while CT and BS were 0.12 (0–0.53), 0.94 (0.87–0.98), and 0.87 (0.78–0.93). For evaluating lymphatic metastases, WBMRI demonstrated a higher sensitivity (p = 0.031) and discrimination compared to CT (0.72 versus 0.56, p = 0.019).
Conclusions
For staging patients with HRPCa, WBMRI outperforms CT in the detection of lymphatic metastases and performs as well as CT and BS in the detection of bone metastases. Further studies are needed to assess the cost effectiveness of WBMRI and the utility of combined PSMA PET and WBMRI.
期刊介绍：
Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management.
Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis.
Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
